ArticleDermatology and therapy2022
Maternal and Perinatal Risk Factors for Infantile Hemangioma: A Matched Case-Control Study with a Large Sample Size.
Article in Dermatology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03331744 (Clinical Characteristics of Infantile Hemangioma), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Characteristics of Infantile Hemangioma: a Prospective Study
Who cites it
13 citing papers in PubMed.
- PHACE syndrome: looking backward and forward.Orphanet journal of rare diseases · 2025Review
- Knowledge, attitudes, and practices on hemangioma among parents of infantile hemangioma patients in South China.Scientific reports · 2025Article
- The Evaluation, Diagnosis, and Management of Infantile Hemangiomas-A Comprehensive Review.Journal of clinical medicine · 2025Review
- Clinical characteristics and risk factors for acute abdomen in patients with abdominal lymphatic malformations.Journal of vascular surgery. Venous and lymphatic disorders · 2025Article
- Targeting ESM1 via SOX4 promotes the progression of infantile hemangioma through the PI3K/AKT signaling pathway.Precision clinical medicine · 2024Article
- Diagnosis and Treatment of Infantile Hemangioma from the Primary Care Paediatricians to the Specialist: A Narrative Review.Children (Basel, Switzerland) · 2024Review
- Infantile hemangiomas: a dermatologist's perspective.European journal of pediatrics · 2024Review
- Clinical characteristics of infantile haemangioma in twins: a retrospective study.BMC pediatrics · 2024Article
- Historical and contemporary management of infantile hemangiomas: a single-center experience.Frontiers in pharmacology · 2024Article
- Infantile Hemangioma: Risk Factors and Management in a Preterm Patient-A Case Report.Reports (MDPI) · 2024Article
- Global research trends of infantile hemangioma: A bibliometric and visualization analysis from 2000 to 2022.Heliyon · 2023Article
- Infantile Hemangioma: A Cross-Sectional Observational Study.Life (Basel, Switzerland) · 2023Article
- Infantile hemangioma models: is the needle in a haystack?Journal of translational medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionInfantile hemangioma (IH) is the most common benign tumor in infancy, but information about its pathogenesis is limited. The aim of this study was to determine maternal and perinatal risk factors for IH.
methodsA total of 1033 IH patients were enrolled in the study between 2017 and 2020. IH patients were matched with controls by sex. Trained investigators collected detailed information from the participants. Logistic regression models were used for multivariate analysis.
resultsThe statistical analysis demonstrated that miscarriage history (odds ratio [OR] = 4.275; 95% confidence interval [CI] [3.195, 5.720]), anemia in pregnancy (OR = 4.228; 95% CI [3.083, 5.799]), preterm premature rupture of membranes (PPROM) (OR = 3.182; 95% CI [1.359, 7.454]), placenta previa (OR = 2.440; 95% CI [1.787, 3.333]), threatened miscarriage (OR = 2.290; 95% CI [1.726, 3.039]), premature rupture of membranes (PROM) (OR = 1.785; P < 0.05), progesterone use (OR = 1.614; P < 0.001) and abnormal amniotic fluid volume (OR = 1.499; P < 0.05) were independent risk factors for IH. Gestational diabetes mellitus (GDM) (OR = 0.607; 95% CI [0.464, 0.794]), multiple gestations (OR = 0.407; 95% CI [0.232, 0.713]), hypothyroidism (OR = 0.407; 95% CI [0.227, 0.730]) and uterine fibroids (OR = 0.393; 95% CI [0.250, 0.618]) may reduce the risk of IH.
conclusionsMaternal and perinatal factors are closely associated with IH occurrence. Our study provides reliable clues to guide further exploration of the pathogenesis of IH.
trial registrationClinicalTrials.gov, NCT03331744. Infantile hemangioma is the most common benign tumor in children, which seriously affects appearance and function and even threatens life. The pathogenesis is not clear, a detailed case-control study of the maternal and perinatal periods with a large sample size will facilitate the development of individualized and precise treatment, early and timely interventions for high-risk children and improvement of prognosis. Our study found that miscarriage history, anemia in pregnancy, preterm premature rupture of membranes (PPROM), placenta previa, threatened miscarriage, premature rupture of membranes (PROM), progesterone use and abnormal amniotic fluid volume were independent risk factors for IH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.